Bristol Myers Squibb (BMY) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of the factors that might affect the near-term performance of the ...

We recently published a list of 10 Stocks That Are Close To Becoming Dividend Aristocrats. In this article, we are going to ...

Income investors are drawn to Aristocrats because these stocks have consistently increased their dividends for decades.

Bristol-Myers Squibb (NYSE: BMY) is the kind of stock that potentially has a lot to offer to investors looking for ...

Bristol Myers Squibb sues HRSA, claiming its rejection of a rebate model for 340B pricing violates federal law. The lawsuit highlights concerns over program abuse and regulatory overreach.

Wolfe Research has recently initiated Bristol-Myers Squibb Co (BMY) stock to Peer Perform rating, as announced on November 15, 2024, according to Finviz. Earlier, on November 13, 2024, Daiwa ...

There is more to the comparison, and in the sections below, we discuss why we think BMY will outperform JNJ in the next three ...

Prime Medicine's strategic collaboration with Bristol Myers provided $55 million in cash upfront. Read why I upgrade PRME stock from hold to buy.

Bristol-Myers Squibb's price continues to rise due to a confluence of factors, not the least of which is an earnings surprise in Q3 2024. Learn more on BMY stock here.

On Friday, Bristol-Myers Squibb Co (BMY) stock saw a modest uptick, ending the day at $58.87 which represents a slight increase of $0.64 or 1.10% from the prior close of $58.23. The stock opened at ...

Leerink Partners analyst David Risinger has maintained their bullish stance on BMY stock, giving a Buy rating on November 19.Don't Miss our ...

StartFragment ...